Vaccine effectiveness of mRNA-1345 against RSV-associated hospitalization and medically attended acute respiratory illness among US veterans, 2025–2026
Vaccine·
- DOI
- 10.1016/j.vaccine.2026.128882
- PMID
- 42424857
- PMCID
- —
- OpenAlex
- W7167831625
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The findings suggest mRNA-1345 provides substantial real-world protection against RSV-related hospitalization and healthcare utilization in older adults, supporting the vaccine's value for reducing RSV disease burden in high-risk populations.
Structured evidence summary
Research question
The study assessed real-world vaccine effectiveness of mRNA-1345 (mRESVIA) against RSV-associated hospitalization and medically attended acute respiratory illness among US veterans aged 50 years or older during the 2025-2026 respiratory season.
Study design
A retrospective test-negative case-control study was conducted using Veterans Health Administration electronic health records, estimating vaccine effectiveness against RSV-positive outcomes using conditional logistic regression.
Population and setting
The study included veterans aged 50 years or older with acute respiratory illness who underwent RSV testing within the Veterans Health Administration system during the 2025-2026 respiratory season.
Main findings
Among 3673 RSV cases and 14,566 matched controls, vaccine effectiveness against RSV-positive ARI-associated hospitalization was 85% (95% CI: 39%-96%). Effectiveness estimates were 65% (95% CI: 45%-77%) against any medically attended RSV-ARI, 57% (95% CI: 28%-74%) against emergency/urgent care visits, and 71% (95% CI: 19%-90%) against outpatient visits.
Public-health relevance
The findings suggest mRNA-1345 provides substantial real-world protection against RSV-related hospitalization and healthcare utilization in older adults, supporting the vaccine's value for reducing RSV disease burden in high-risk populations.
Important limitations
This summary is limited to the supplied single-article abstract/metadata and requires access to the original paper for decision-grade interpretation, as no explicit limitations were stated in the abstract.
GIDS interpretation
This single-article summary documents vaccine effectiveness findings for mRNA-1345 from one healthcare system during one season; broader generalizability and contextualization with other surveillance data would require the full paper.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 10 auditable classifier relationships to diseases, places, topics, and study design.